-
CCHIO 2024丨Dr. Man Li: Systematic Breast Cancer Treatment — Precision Medicine Leading the Future
Breast cancer remains a major threat to women’s health, with continuous advancements in treatment strategies being a focal point for the medical community. In China, as the concept of precision medicine gains momentum, systematic breast cancer treatment is gradually moving towards more personalized and precise approaches. At the 2024 Chinese Congress of Holistic Integrative Oncology…
-
CCHIO 2024丨Dr. Nanlin Li: Current Status, Challenges, and Future Directions of Breast Cancer Screening for Chinese Women
Breast cancer remains a major threat to women’s health, and early screening plays a crucial role in reducing both incidence and mortality. However, compared to developed countries in Europe and North America, China still faces numerous challenges in breast cancer screening. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) during the Breast Oncology…
-
CCHIO 2024丨Dr. Yinying Wu: Advances in CLDN18.2-Positive Gastric Cancer Research
At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) held from November 14–17 in Xi’an, Dr. Yinying Wu from The First Affiliated Hospital Xi’an Jiao Tong University delivered a comprehensive lecture titled “Advances in CLDN18.2-Positive Gastric Cancer Research.” The presentation delved into the role of CLDN18.2 protein in gastric cancer, advancements in drug therapies,…
-
CCHIO 2024丨Dr. Yong Zeng: Sharing West China Hospital’s Experience in ERAS for Perioperative Hepatectomy
At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), Dr. Yong Zeng from West China Hospital Sichuan University presented a keynote lecture titled “Advances and Clinical Practice of Enhanced…
-
CSCO 2024 | NEOPRISM-CRC Study PI Discusses “Reducing Toxicity and Enhancing Efficacy” Strategies for Neoadjuvant Immunotherapy in Locally Advanced
Neoadjuvant therapy for locally advanced colorectal cancer has made significant progress over the past 20 years, but it still faces limitations such as adverse reactions, organ dysfunction, and unsatisfactory control of distant metastasis. In recent years, with the improvement of surgical techniques and further development of tumor molecular typing research, how to further improve local…
-
Chinese Expertise at AASLD 2024: Dr. Qin Ning’s Team Achieves New Breakthroughs in CHB Clinical Cure Strategies
The second study evaluated the efficacy of a triple therapy combining TLR-7 agonist TQ-A3334, PD-L1 antibody TQ-B2450, and NA in virologically suppressed CHB patients. The results demonstrated that the triple…
-
Dr. Jun Guo: Reflecting on Progress in Renal Cancer Treatment and Pioneering a New Era of Cellular Therapy for Metastatic Patients
Renal cancer is one of the three major malignancies in the urinary system, with advanced metastatic renal cancer having a poor prognosis and an overall five-year survival rate of less than 20%. Recent advances in targeted therapies and immunotherapies have led to significant improvements in treatment outcomes; however, for patients progressing beyond first-line therapies, the…
-
Dr. Kan Gong: Reflecting on Key Challenges and Hotspots in Renal Cancer Diagnosis and Treatment in China, Exploring New Frontiers in Translational Research | The 8th West China Uro-Oncology Tianfu Academic Conference
Renal cancer is one of the three major malignancies in the urinary system. Early-stage renal cancer often presents with concealed symptoms, making it difficult to differentiate between benign and malignant tumors. Advanced renal cancer primarily relies on targeted or immunotherapy, yet the effectiveness of existing targeted drugs is low, and resistance tends to develop easily.…
Connecting Medical Expertise through Media